491 a Clinical Trial of Nitrosense® Patch for the Treatment of Diabetic Patients With Peripheral Diabetic Neuropathy

Agrawal, R P; Jain, Shreyans; Goyal, Shekhar; Kochar, Anju; Singhal, Sameer; Lindgren, L.; Sthengel, E.

doi:10.1016/s1754-3207(10)70496-x

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with type 2 diabetes suffering from painful diabetic neuropathy, treatment with the NO donors glyceryl trinitrate (39) and isosorbide dinitrate (40) significantly improved pain symptoms, indicative of the beneficial action of NO in diabetic neuropathy. Similar effects were observed when locally applying a NO-releasing cutaneous patch (41). These effects may, however, also be indirectly explained by variations in local microcirculation: transient changes in sciatic nerve microcirculation were observed in response to NO in animals with STZ-induced diabetes developing diabetic neuropathy (42).…”

Section: Neuropathymentioning

confidence: 61%

Gasotransmitters in Vascular Complications of Diabetes

et al. 2016

View full text Add to dashboard Cite

In the past decades three gaseous signaling molecules—so-called gasotransmitters—have been identified: nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). These gasotransmitters are endogenously produced by different enzymes in various cell types and play an important role in physiology and disease. Despite their specific functions, all gasotransmitters share the capacity to reduce oxidative stress, induce angiogenesis, and promote vasorelaxation. In patients with diabetes, a lower bioavailability of the different gasotransmitters is observed when compared with healthy individuals. As yet, it is unknown whether this reduction precedes or results from diabetes. The increased risk for vascular disease in patients with diabetes, in combination with the extensive clinical, financial, and societal burden, calls for action to either prevent or improve the treatment of vascular complications. In this Perspective, we present a concise overview of the current data on the bioavailability of gasotransmitters in diabetes and their potential role in the development and progression of diabetes-associated microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular (cerebrovascular, coronary artery, and peripheral arterial diseases) complications. Gasotransmitters appear to have both inhibitory and stimulatory effects in the course of vascular disease development. This Perspective concludes with a discussion on gasotransmitter-based interventions as a therapeutic option.

show abstract

Section: Neuropathymentioning

confidence: 61%

Gasotransmitters in Vascular Complications of Diabetes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The occurrence of oxidative stress is a result of an imbalance between reactive oxygen species (ROS) and antioxidants, leading to increased radical production and decreased antioxidant rates (22,23). MDA plays a role in lipid peroxidation (24) and is commonly utilized as a biomarker in the assessment of oxidative stress among T2DM patients (25,26). In chronic illnesses like T2DM and its complications, an abundance of MDA is typically produced (27).…”

Section: Discussionmentioning

confidence: 99%

Association between vitamin D status and malondialdehyde in T2DM patients with painful diabetic peripheral neuropathy

Alan Bapeer Hassan,

Ali Hussein Ahmed Al-Dosky

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

“…A clinical study revealed a decreased serum prolidase enzyme activity, which may be associated with increased NO levels and oxidative stress in diabetic patients with neuropathy [96] . In a randomized placebo-controlled study, a NO-releasing patch (NitroSense Derma Protect) showed a significant reduction in pain of PDN patients [97] .…”

Section: Expert Opinionmentioning

confidence: 99%

Alleviation of pain in painful diabetic neuropathy

Tajti

Delia

Majláth

et al. 2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction: Painful diabetic neuropathy (PDN) is a disabling pain condition. Its pathomechanism remains unknown, but a sensitization and neuronal hyperexcitabilty have been suggested. Only symptomatic pharmacological pain-alleviation treatment is currently available. Areas covered:The origin of PDN is enigmatic, and the evidence-based therapeutic guidelines therefore consist only of antidepressants and antiepileptics as first-line recommended drugs. This article relates to a MEDLINE/PubMed systematic search (2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). Expert opinion:The results of the meta-analysis from the aspect of the efficacy of amitriptyline, duloxetine, venlafaxine, gabapentin and pregabalin are favorable, but the placebo response rate is relatively high in patients with neuropathic pain. For personalization of the medication of PDN patients, the optimum dosing, the genotyping of the metabolizing enzymes and optimum biomarkers are needed. As concerns the future perspectives, specific sodium channel subtype inhibitors acting on peripheral nociceptive neurons or modified Ttype voltage-gated calcium channel blockers may be promising targets for pharmaceutical innovations. Another attractive strategy for the treatment is based on the effects of monoclonal antibodies against nerve growth factor, sodium channel, specific receptor and cytokines. Botulinum toxin A, capsaicin patch and spinal cord stimulation therapies are the nearest future therapeutic options for the treatment of PDN patients.

show abstract

491 a Clinical Trial of Nitrosense® Patch for the Treatment of Diabetic Patients With Peripheral Diabetic Neuropathy

Cited by 4 publications

References 0 publications

Gasotransmitters in Vascular Complications of Diabetes

Gasotransmitters in Vascular Complications of Diabetes

Association between vitamin D status and malondialdehyde in T2DM patients with painful diabetic peripheral neuropathy

Alleviation of pain in painful diabetic neuropathy

Contact Info

Product

Resources

About